CN110876807A - Spray containing surfactant for anticholinergic medicine - Google Patents
Spray containing surfactant for anticholinergic medicine Download PDFInfo
- Publication number
- CN110876807A CN110876807A CN201811039446.XA CN201811039446A CN110876807A CN 110876807 A CN110876807 A CN 110876807A CN 201811039446 A CN201811039446 A CN 201811039446A CN 110876807 A CN110876807 A CN 110876807A
- Authority
- CN
- China
- Prior art keywords
- spray
- pharmaceutical composition
- surfactant
- anticholinergic
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
Abstract
The invention relates to a tiotropium bromide spray for treating respiratory diseases, in particular asthma, chronic obstructive pneumonia, tracheitis and the like, wherein an inhalable surfactant can enable the spray particle size, the spray time and the spray speed of a composition to be more suitable by adjusting the surface tension of a spray pharmaceutical composition of an anticholinergic drug of M1, M2 and/or M3 receptors which do not contain a propellant.
Description
The technical field is as follows:
the invention relates to a tiotropium bromide spray for treating respiratory diseases, in particular asthma, chronic obstructive pneumonia, tracheitis and the like, wherein an inhalable surfactant can enable the spray particle size, the spray time and the spray speed of a composition to be more suitable by adjusting the surface tension of a spray pharmaceutical composition of an anticholinergic drug of M1, M2 and/or M3 receptors which do not contain a propellant.
Background art:
asthma is a chronic airway inflammation characterized by reversible airway obstruction and airway reactivity increase, the airway obstruction is caused by two factors of secretion increase, mucosal edema and inflammation stimulation smooth muscle spasm caused by bronchial mucosa inflammation, and the airway reactivity increase is also a result of bronchial epithelial cell injury caused by airway inflammation.
Asthma is a chronic airway inflammation characterized by reversible airway obstruction and airway reactivity increase, the airway obstruction is caused by two factors of secretion increase, mucosal edema and inflammation stimulation smooth muscle spasm caused by bronchial mucosa inflammation, and the airway reactivity increase is also a result of bronchial epithelial cell injury caused by airway inflammation.
Among them, potent anticholinergic drugs having high selectivity for airway muscarinic acetylcholine receptors (M receptors) have been attracting attention in recent years, the transmitter of parasympathetic postganglionic neurons that innervate the airways is acetylcholine, and the receptor on the effector is the M receptor. From the pharmacological point of view, they are classified into M1, M2, M3 and M4 according to their affinity for receptor subtype-specific antagonists. Among them, the receptor M1, which has high affinity for pirenzepine and 4-DAMP; m2 receptor with high affinity for AF-DXll 6; the receptor with high affinity for 4-DAMP is called M3 receptor; the M4 receptor is called as the receptor with high affinity with P-F-HHSID. However, there are at least 5 different genes encoding mAChR, designated m1, m2, m3, m4, m 5, and the human genes have chromosomal locations 1lql 2-13, 7q 35-36, lq 43-44, 11q 12-11.2, 15q 26, respectively. M1, M2, M3, and M4 correspond to pharmacological M1, M2, M3, and M4, respectively. The protein expressed by the M5 gene exists only in an independent area of the brain, and the corresponding functional pharmacological expression is not found at present, so that M5 is not available temporarily. Airway M receptors play important roles in regulating airway smooth muscle tone, mucus glycoprotein and mucus synthesis and secretion, mucociliary clearance, and the like. The distribution and the function of each subtype of M receptor in the air passage are closely related, the M3 receptor is mainly used for dominating the submucosal gland, the M2 receptor has a regulation effect on secretion, and the direct effects of the M4 receptor and the M5 receptor are not found at present. Cholinergic innervation may also occur in goblet cells. M receptor antagonists are capable of dilating bronchi and inhibiting mucus secretion, and are important in the treatment of COPD, bronchial asthma, and the like. Anticholinergic agents have been used as first line agents in the treatment of COPD.
M1, M2 or M3 receptor anticholinergic drugs are common drugs for treating asthma, Chronic Obstructive Pulmonary Disease (COPD) and the like, and include ipratropium bromide, tiotropium bromide and the like.
Ipratropium bromide is a drug with a relatively short duration of action, typically only 4 to 8 hours. Administration may be by means of a Metered Dose Inhaler (MDI) or an aerosol. In addition, it can be used as the maintenance drug of COPD by putting salbutamol and the combined preparation prepared in the same device. It is mainly limited in asthma treatment to control the symptoms at the time of acute attack. Tiotropium bromide appeared in the early 2000 years and its duration of action was at least 24 hours, so once daily dosing was recommended as a maintenance medication for COPD. Tiotropium bromide can be inhaled in the form of a dry powder formulation (DPI), but recently a new administration form of Soft Mist Inhaler (SMI) has emerged.
Common respiratory tract inhalation preparations for treating asthma and the like comprise aerosol and dry powder inhalants, wherein the aerosol refers to a preparation which is packaged in a pressure-resistant container with a special valve system together with emulsion or suspension containing medicaments and a proper propellant, and the content is sprayed out in the form of mist by the pressure of the propellant when the aerosol is used for lung inhalation; the dry powder inhalant is a drug dosage form which is prepared by one or more than one drug, enters respiratory tract in a dry powder form after being administrated by a special administration device and plays a role of whole body or local; the aerosol is liquid and uses propellant, while the dry powder inhalant is solid containing carrier, there are obvious differences between two formulations from the view point of formulation, the key point of the aerosol formulation is to study the uniformity and stability of emulsion or suspension, and the key point of the dry powder inhalant formulation is to study the particle science technology between different solid particles. Spray refers to a formulation that does not contain a propellant and sprays a liquid into a mist by means of the pressure of a manual pump. It is obvious that the spray and the aerosol are most different from the former spray by external force, and the latter spray by internal pressure and propellant. The latter has the following disadvantages compared with the former: 1 are costly (due to the internal pressure vessels, valve systems and special production equipment). 2 the propellant has refrigerating effect, and is not suitable for stimulation caused by being used on wounded skin wound for many times. 3 the propellant has certain toxicity and is not suitable for patients with heart disease to use as inhalation aerosol. 4, explosion easily occurs.
Ipratropium bromide is a drug with a relatively short duration of action, typically only 4 to 8 hours. Administration may be by means of a Metered Dose Inhaler (MDI) or an aerosol. In addition, it can be used as the maintenance drug of COPD by putting salbutamol and the combined preparation prepared in the same device. It is mainly limited in asthma treatment to control the symptoms at the time of acute attack. Tiotropium bromide appeared in the early 2000 years and its duration of action was at least 24 hours, so once daily dosing was recommended as a maintenance medication for COPD. Tiotropium bromide can be inhaled in the form of a dry powder formulation (DPI), but recently a new administration form of Soft Mist Inhaler (SMI) has emerged. Tiotropium bromide (tiotropium bromide) is a given once daily LAMA, increasing a range of functions and improving patient outcome in COPD patients, reducing moderate and severe exacerbations, reducing the number of episodes and reducing mortality.
Ondaterol (Olodatero) is a novel once daily LABA that is specifically designed by Boringer Invitrogen, Germany, for combination with tiotropium bromide, and has a duration of 24 hours, and is capable of improving the lung function, improving the symptoms and improving exercise capacity of the patient. Tiotropium bromide and olodaterol have complementary pharmacokinetic and pharmacodynamic characteristics, and a once-daily fixed dose combination can treat COPD patients to maintain bronchiectasis.
Common respiratory tract inhalation preparations for treating asthma and the like comprise aerosol and dry powder inhalants, wherein the aerosol refers to a preparation which is packaged in a pressure-resistant container with a special valve system together with emulsion or suspension containing medicaments and a proper propellant, and the content is sprayed out in the form of mist by the pressure of the propellant when the aerosol is used for lung inhalation; the dry powder inhalant is a drug dosage form which is prepared by one or more than one drug, enters respiratory tract in a dry powder form after being administrated by a special administration device and plays a role of whole body or local; the aerosol is liquid and uses propellant, while the dry powder inhalant is solid containing carrier, there are obvious differences between two formulations from the view point of formulation, the key point of the aerosol formulation is to study the uniformity and stability of emulsion or suspension, and the key point of the dry powder inhalant formulation is to study the particle science technology between different solid particles.
According to the actual situation of inhalation of patients suffering from asthma and COPD, the inhalation device as an ideal inhalation device should realize easy inhalation, ensure high-efficiency medicine deposition and airway (avoiding oral cavity deposition) and be convenient to operate and carry. In order to achieve the above effects, the inhalation device should have the characteristics of low inhalation starting flow rate, slow fogging release, low-speed operation of aerosol, less deposition in the oropharynx, ideal particle content, high lung deposition rate, simple operation, proper size and the like. The faster mist speed and the longer release time are not favorable for the particles to pass through the tortuous path between the oropharynx and the trachea, so that the lung deposition rate is easy to reduce, and the oropharynx deposition rate is improved.
In recent years, new soft mist inhalant silihua (tiotropium bromide) and device (nerware) from germany pharmaceutical giant bristle berg invager company (BI) have been marketed globally.
Soft mist inhalers are an upgraded version of aerosols. Compared with a soft mist inhalant, the traditional inhalant has short spray duration which is only 0.2-0.3 seconds, and many patients with poor coordination ability cannot inhale the inhalant sufficiently. Meanwhile, the traditional atomizer is inconvenient to operate and not easy to carry; the pressure quantitative inhalant needs a propellant and is not environment-friendly. The soft mist inhalant realizes active spraying through the device, does not need a patient to inhale, has longer duration of the aerosol, is prolonged to more than 1.2 seconds, has slow aerosol injection speed, has ideal particle content of up to 70 percent, ensures the high-efficiency deposition of the medicine in the lung, reaches 51.6 percent, is easy to carry, and greatly improves the compliance of the patient.
Compared with the conventional aerosol device, the soft aerosol is driven by mechanical potential energy (without using a propellant) to trigger active spraying, has long duration and slower running speed, can provide longer inhalation time for a patient, and has low requirement on the synchronism of the coordination of the eyes and the mouth.
The soft fogging concentrate is a new formulation with the advantage of treating respiratory diseases, has higher technical threshold on an inhalation device, has higher technical difficulty for drug imitation, and can better avoid malignant competition caused by excess productivity.
CN03808233.0 discloses tiotropium salts in pharmaceutical formulations at a concentration between 0.01 g per 100ml of formulation and 0.06 g per 100ml of formulation, water as the sole solvent, and an acid to adjust the pH between 2.7 and 3.1, preferably between 2.8 and 3.05, together with a pharmacologically acceptable bacteriostatic agent, such as benzalkonium chloride, and a pharmacologically acceptable complexing agent, such as salts of ethylenediaminetetraacetic acid. In which edta or salt has the function of altering spray abnormalities, such as those that occur in aerosols without edta or salt addition after an interruption of 3 or more days, for example, the spray droplet size may change, so that the patient's precise dosage may be affected, possibly as a result of fine deposits in the nozzle opening area.
However, none of these documents describes the effect of surface tension on the spray particle size, spray time and spray rate of such propellant-free sprayable pharmaceutical compositions.
Chinese patents CN200580012621.0 and CN200680037725.1 disclose technical schemes of tiotropium bromide oxdalterol sprays.
The invention content is as follows:
it has been surprisingly found that in a composition comprising tiotropium bromide or its hydrate, an inhalable surfactant, an inorganic acidic PH adjuster and water, the surface tension of the inhalable surfactant is adjusted to provide a better control of the spray particle size of the propellant-free pharmaceutical spray composition, thereby extending the spray time and reducing the spray rate.
A propellant-free spray pharmaceutical composition of an anticholinergic drug of M1, M2 and/or M3 receptor, which is characterized in that the composition consists of the anticholinergic drug, an inhalable surfactant, an inorganic acidic pH value regulator and water, wherein the inhalable surfactant regulates the surface tension of the composition to be 52 +/-2 mN/M and the pH to be 3.0 +/-0.2.
The pharmaceutical composition is characterized in that the anticholinergic drug is tiotropium, ipratropium halide or hydrate thereof.
The pharmaceutical composition is characterized in that the halogen compound of the anticholinergic drug tiotropium and ipratropium is tiotropium bromide, ipratropium bromide and hydrate thereof.
The pharmaceutical composition is characterized in that the dosage of the M1, M2 and/or M3 receptor anticholinergic drug is less than or equal to 2.5 mg/ml.
The above pharmaceutical composition, characterized in that the manner of measuring surface tension is a hanging drop method.
The pharmaceutical composition is characterized by also comprising a bacteriostatic agent. The medicinal composition is characterized in that the bacteriostatic agent is one of benzalkonium chloride and benzalkonium bromide. The medicinal composition is characterized in that the bacteriostatic agent is benzalkonium chloride. The medicinal composition is characterized in that the content of the bacteriostatic agent is 8-12mg/100 ml. The medicinal composition is characterized in that the bacteriostatic agent is one of benzalkonium chloride and benzalkonium bromide, and the content of the benzalkonium chloride or benzalkonium bromide is 8-12mg/100 ml.
The composition is characterized in that the inorganic acidic pH value regulator is one or more of hydrochloric acid, methanesulfonic acid, benzoic acid and acetic acid.
The composition is characterized in that the β 2 adrenergic receptor agonist is salbutamol, olodaterol, salmeterol, indacaterol, formoterol, procaterol, and pharmaceutically acceptable salts of terbutaline, the composition is characterized in that the β adrenergic receptor agonist is salbutamol sulfate, olodaterol hydrochloride, salmeterol xinafoate, indacaterol maleate, formoterol fumarate, procaterol hydrochloride, and pharmaceutically acceptable salts of terbutaline sulfate.
Use of an inhalable surfactant as an adjuvant to modify the spray particle size and spray velocity of a spray pharmaceutical composition of a propellant-free M1, M2 and/or M3 receptor anticholinergic drug.
The medicinal composition is characterized in that the inhalable surfactant is one or more of dipalmitoylphosphatidylcholine, phosphatidylglycerol, hexadecanol, tyloxapol, phospholipid and dipalmitoylphosphatidylglycerol, and the phospholipid is soybean phospholipid.
The pharmaceutical composition is characterized by a pH of 3.0 + -0.2.
As the anticholinergic receptor drug monohydrate is completely dissolved in water in the technical scheme range, the preparation has no influence on the preparation like the anticholinergic receptor drug.
The surface tension in the present invention is measured using the pendant drop method.
Detailed Description
The surface tension in the examples of the invention was determined by the pendant drop method at 20 ℃ using the DSA25S from Kruss (kluss) germany.
Example 1
The preparation method comprises the following steps: tiotropium bromide or tiotropium bromide monohydrate, the pharmaceutical salt of olodaterol and water with the pH value adjusted by hydrochloric acid are mixed uniformly, and the surface tension of the whole solution is adjusted to the following table by an aqueous solution of an inhalable surfactant.
100ml of pharmaceutical formulation:
example 2
The preparation method comprises the following steps: tiotropium bromide or tiotropium bromide monohydrate, the pharmaceutical salt of the olodaterol, the bacteriostatic agent and water with the pH value adjusted by hydrochloric acid are mixed uniformly, and the surface tension of the aqueous solution is adjusted to the following table by using the surfactant. 100ml of pharmaceutical formulation:
example 3
The preparation method comprises the following steps: tiotropium bromide or tiotropium bromide monohydrate, the pharmaceutical salt of the olodaterol, the bacteriostatic agent and water with the pH value adjusted by hydrochloric acid are mixed uniformly, and the surface tension of the aqueous solution is adjusted to the following table by using the surfactant.
100ml of pharmaceutical formulation:
example 4
The preparation method comprises the following steps: tiotropium bromide or tiotropium bromide monohydrate, the pharmaceutical salt of the olodaterol, the bacteriostatic agent and water with the pH value adjusted by hydrochloric acid are mixed uniformly, and the surface tension of the aqueous solution is adjusted to the following table by using the surfactant.
100ml of pharmaceutical formulation:
example 5
The preparation method comprises the following steps: isoipratropium bromide or ipratropium bromide monohydrate is mixed uniformly with water adjusted to pH with hydrochloric acid, and the surface tension of the overall solution is adjusted to the table below with an aqueous solution of an inhalable surfactant.
100ml of pharmaceutical formulation:
example 6
The preparation method comprises the following steps: the ipratropium bromide or ipratropium bromide monohydrate, the bacteriostatic agent and the water with the pH value adjusted by hydrochloric acid are mixed evenly, and the surface tension of the aqueous solution is adjusted to the following table by the surfactant. 100ml of pharmaceutical formulation:
example 7
The preparation method comprises the following steps: the ipratropium bromide or ipratropium bromide monohydrate, the bacteriostatic agent and the water with the pH value adjusted by hydrochloric acid are mixed evenly, and the surface tension of the aqueous solution is adjusted to the following table by the surfactant.
100ml of pharmaceutical formulation:
example 1
The preparation method comprises the following steps: tiotropium bromide or tiotropium bromide monohydrate is mixed homogeneously with water adjusted to PH with hydrochloric acid, and the surface tension of the overall solution is adjusted to the table below with an aqueous solution of an inhalable surfactant. 100ml of pharmaceutical formulation:
example 2
The preparation method comprises the following steps: tiotropium bromide or tiotropium bromide monohydrate, bacteriostatic agent and water with pH value regulated with hydrochloric acid are mixed homogeneously, and surfactant is used to regulate the surface tension of the water solution to the table below.
100ml of pharmaceutical formulation:
example 3
The preparation method comprises the following steps: tiotropium bromide or tiotropium bromide monohydrate, bacteriostatic agent and water with pH value regulated with hydrochloric acid are mixed homogeneously, and surfactant is used to regulate the surface tension of the water solution to the table below.
100ml of pharmaceutical formulation:
comparative example 1
The preparation method comprises the following steps: tiotropium bromide or tiotropium bromide monohydrate, the pharmaceutical salt of olodaterol and water with the pH value adjusted by hydrochloric acid are mixed uniformly, and the surface tension of the whole solution is adjusted to the following table by an aqueous solution of an inhalable surfactant.
100ml of pharmaceutical formulation:
comparative example 2
The preparation method comprises the following steps: isoipratropium bromide or ipratropium bromide monohydrate is mixed uniformly with water adjusted to pH with hydrochloric acid, and the surface tension of the overall solution is adjusted to the table below with an aqueous solution of an inhalable surfactant.
100ml of pharmaceutical formulation:
comparative example 3
The preparation method comprises the following steps: tiotropium bromide or tiotropium bromide monohydrate is mixed homogeneously with water adjusted to PH with hydrochloric acid, and the surface tension of the overall solution is adjusted to the table below with an aqueous solution of an inhalable surfactant.
100ml of pharmaceutical formulation:
spray particle size test
The pharmaceutical compositions obtained in examples and comparative examples were sprayed with a BI spray device, neruole, and the spray droplet size was measured with a german SYMPATEC laser particle sizer (HELOS-spray). The detection method comprises spraying 2 times before discarding the medicinal composition, measuring the average spray droplet diameter after spraying the medicinal composition, standing for 4 days, spraying 10 times again, and measuring the average spray droplet diameter.
Spray time test
The test method comprises the following steps: the pharmaceutical compositions obtained in examples and comparative examples were sprayed using a spray device available from BI corporation, nerolida, and the time from the start to the end of spraying was measured 10 times and averaged.
Spray velocity test
An experimental instrument: particle Dynamics Analysis (PDA) from Danish Dantec Dynamics A/S Using phase Doppler technology
The test method comprises the following steps: the pharmaceutical compositions obtained in examples and comparative examples were sprayed using a BI spray device-nerolides, and the axial velocity of the spray was measured at 0.8 second after the start of spraying.
The above examples demonstrate that the surfactant can properly change the surface tension of the spray pharmaceutical composition of the M1, M2 and/or M3 receptor anticholinergic drug without the propellant, and the surface tension of the pharmaceutical composition is verified to have better effect by a spray particle size test, a spray time test and a spray speed test.
Claims (10)
1. A propellant-free spray pharmaceutical composition of an anticholinergic drug of M1, M2 and/or M3 receptor, which is characterized in that the composition consists of the anticholinergic drug, an inhalable surfactant, an inorganic acidic pH value regulator and water, wherein the inhalable surfactant regulates the surface tension of the composition to be 52 +/-2 mN/M and the pH to be 3.0 +/-0.2.
2. The pharmaceutical composition of claim 1, wherein the anticholinergic is tiotropium, a halogen compound of ipratropium, or a hydrate thereof.
3. The pharmaceutical composition of claim 1, wherein the anticholinergic agent tiotropium, a halogen compound of ipratropium, is tiotropium bromide, ipratropium bromide, or a hydrate thereof.
4. The pharmaceutical composition according to claim 1, wherein the dosage of the M1, M2 and/or M3 receptor anticholinergic agent is 2.5mg/ml or less.
5. The pharmaceutical composition of claim 1, wherein the means for measuring surface tension is by hanging drop method.
6. The pharmaceutical composition of claim 1, further comprising a bacteriostatic agent.
7. The pharmaceutical composition of claim 6, wherein the bacteriostatic agent is one of benzalkonium chloride and benzalkonium bromide.
8. The composition of claim 1 wherein the spray pharmaceutical composition is comprised of β 2 adrenergic receptor agonist.
9. Use of an inhalable surfactant as an adjuvant to modify the spray particle size and spray velocity of a spray pharmaceutical composition of a propellant-free M1, M2 and/or M3 receptor anticholinergic drug.
10. The pharmaceutical composition of claim 1, wherein the PH is 3.0 ± 0.2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811039446.XA CN110876807A (en) | 2018-09-06 | 2018-09-06 | Spray containing surfactant for anticholinergic medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811039446.XA CN110876807A (en) | 2018-09-06 | 2018-09-06 | Spray containing surfactant for anticholinergic medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110876807A true CN110876807A (en) | 2020-03-13 |
Family
ID=69727367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811039446.XA Pending CN110876807A (en) | 2018-09-06 | 2018-09-06 | Spray containing surfactant for anticholinergic medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110876807A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114259481A (en) * | 2021-11-26 | 2022-04-01 | 南京华盖制药有限公司 | Compound inhalation solution of odaterol |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006108556A2 (en) * | 2005-04-15 | 2006-10-19 | Pari Pharma Gmbh | Pharmaceutical aerosol composition |
| CN101052388A (en) * | 2004-09-09 | 2007-10-10 | 希普拉有限公司 | Medicinal composition containing imitating beta adrenergic agent and anti cholinergic agent |
| CN104306361A (en) * | 2014-09-24 | 2015-01-28 | 万特制药(海南)有限公司 | Tiotropium bromide-containing inhalable solution |
| CN105125542A (en) * | 2015-08-23 | 2015-12-09 | 杭州紫金医药科技有限公司 | Medicine composition with tiotropium bromide and formoterol, application of medicine composition and preparation |
| CN105362220A (en) * | 2014-08-08 | 2016-03-02 | 深圳君圣泰生物技术有限公司 | Preparation, preparation method and uses thereof |
| CN105435227A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Liquid preparation composition and preparation method and use and solid preparation thereof |
| CN105434346A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Preparation composition and preparation method and use thereof |
| CN105435232A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Liquid preparation composition and preparation method and use and solid preparation thereof |
| WO2016185282A1 (en) * | 2015-05-18 | 2016-11-24 | Glenmark Specialty S.A. | Tiotropium inhalation solution for nebulization |
| CN106667975A (en) * | 2017-02-15 | 2017-05-17 | 杭州百诚医药科技股份有限公司 | Preparation method of ipratropium bromide solution for inhalation |
-
2018
- 2018-09-06 CN CN201811039446.XA patent/CN110876807A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101052388A (en) * | 2004-09-09 | 2007-10-10 | 希普拉有限公司 | Medicinal composition containing imitating beta adrenergic agent and anti cholinergic agent |
| WO2006108556A2 (en) * | 2005-04-15 | 2006-10-19 | Pari Pharma Gmbh | Pharmaceutical aerosol composition |
| CN105362220A (en) * | 2014-08-08 | 2016-03-02 | 深圳君圣泰生物技术有限公司 | Preparation, preparation method and uses thereof |
| CN105435227A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Liquid preparation composition and preparation method and use and solid preparation thereof |
| CN105434346A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Preparation composition and preparation method and use thereof |
| CN105435232A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Liquid preparation composition and preparation method and use and solid preparation thereof |
| CN104306361A (en) * | 2014-09-24 | 2015-01-28 | 万特制药(海南)有限公司 | Tiotropium bromide-containing inhalable solution |
| WO2016185282A1 (en) * | 2015-05-18 | 2016-11-24 | Glenmark Specialty S.A. | Tiotropium inhalation solution for nebulization |
| CN105125542A (en) * | 2015-08-23 | 2015-12-09 | 杭州紫金医药科技有限公司 | Medicine composition with tiotropium bromide and formoterol, application of medicine composition and preparation |
| CN106667975A (en) * | 2017-02-15 | 2017-05-17 | 杭州百诚医药科技股份有限公司 | Preparation method of ipratropium bromide solution for inhalation |
Non-Patent Citations (4)
| Title |
|---|
| 何雄奎 主编: "《高效施药技术与机具》", vol. 1, 28 February 2012, 中国农业大学出版社, pages: 433 - 436 * |
| 孙建国 等: "《临床内分泌诊疗技术》", vol. 1, 30 September 2017, 科学技术文献出版社, pages: 443 * |
| 辛喆 主编: "《汽车拖拉机发动机原理》", vol. 2, 31 January 2015, 中国农业大学出版社, pages: 159 * |
| 邹力行: "《陶瓷生产技术问答》", vol. 1, 31 August 1993, 中国建筑工艺出版社, pages: 248 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114259481A (en) * | 2021-11-26 | 2022-04-01 | 南京华盖制药有限公司 | Compound inhalation solution of odaterol |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110876722A (en) | Tiotropium bromide and oxdarterol spray containing surfactant | |
| TWI758617B (en) | Aerosol pharmaceutical composition comprising glycopyrronium salt and indacaterol salt, its preparation method and use | |
| JP2008513444A (en) | Methods for targeted delivery of lidocaine and other local anesthetics and treatment of cough and cough attacks | |
| CA2417973A1 (en) | Formulations of mometasone and a bronchodilator for pulmonary administration | |
| JP2002532520A (en) | Compounds and methods for airway disease treatment and airway drug delivery | |
| KR20140069091A (en) | Treating cough and tussive attacks | |
| US11642333B2 (en) | Inhalable formulation of a solution containing vilanterol trifenatate and umeclidinium bromide | |
| RU2013151018A (en) | INTRODUCTION OF ILOPROSTA AS AEROSOL BOLUSES | |
| CN110876807A (en) | Spray containing surfactant for anticholinergic medicine | |
| CN110876721A (en) | Tiotropium bromide spray containing surfactant | |
| CN110876723A (en) | Isopropyl tropium bromide spray containing surfactant | |
| CN110876724A (en) | Application of edetate for properly changing surface tension of tiotropium bromide and oxdarterol spray | |
| CN110302158B (en) | Tiotropium bromide aerosol composition and preparation method thereof | |
| CN110302157B (en) | Ipratropium bromide aerosol composition and preparation method thereof | |
| CN110302184B (en) | Application of lysine in quaternary ammonium salt M receptor antagonist aerosol | |
| US20210220367A1 (en) | Inhalable formulation of a solution containing glycopyrrolate and olodaterol hydrochloride | |
| CN110876720A (en) | Application of edetate to properly change surface tension of tiotropium bromide spray | |
| WO2020019953A1 (en) | Aerosol pharmaceutical composition containing a glycopyrrolate salt, preparation method therefor, and uses thereof | |
| WO2010009288A1 (en) | Compositions and uses of antiviral active pharmaceutical agents | |
| CN106390128B (en) | Use of beta-adrenergic inverse agonists for smoking cessation | |
| CN110302185A (en) | A kind of Ipratropium Bromide aerosol combination and preparation method thereof without propellant | |
| JP7309791B2 (en) | Inhalation formulations of isoglycyrrhizic acid or its salts and their use in the manufacture of medicaments for treating respiratory diseases | |
| EP2957551B1 (en) | Dry powder formulations comprising vilanterol | |
| US20200405700A1 (en) | Inhalable formulation of a solution containing formoterol fumarate and aclidinium bromide | |
| WO2023206444A1 (en) | Treprostinil soft mist inhalant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200313 |
|
| RJ01 | Rejection of invention patent application after publication |